Enanta Pharmaceuticals, Inc Stock Prediction
AI-powered sentiment analysis and prediction trends for ENTA, updated each market day.
ENTA AI Sentiment
AI sees no strong directional signal for Enanta Pharmaceuticals, Inc stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Enanta Pharmaceuticals, Inc
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Sector
Exchange
Market Cap
$404,819,848
Cap Tier
Employees
120
Headquarters
WATERTOWN, MA
Listed Since
March 21, 2013
Website
ENTA Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ENTA Volatility
Enanta Pharmaceuticals, Inc has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
